Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
Aytu is committed to better health for men and women here at home and worldwide. W...
Aytu is committed to better health for men and ...
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...
Enlivex is a clinical stage immunotherapy compa...
Developing flexible and affordable genetic testing that improves the everyday live...
Developing flexible and affordable genetic test...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...
Millendo Therapeutics is a late-stage biopharma...
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying a ...
SpringWorks Therapeutics is a clinical-stage bi...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Join the National Investor Network and get the latest information with your interests in mind.